TuHURA Biosciences (HURA) CEO James Bianco gifts 150,000 shares to adult sons

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

TuHURA Biosciences Chief Executive Officer James A. Bianco reported a bona fide gift of 150,000 shares of TuHURA Biosciences common stock. The shares were transferred on May 28, 2026 and, according to the disclosure, were gifted to adult sons who do not share the same household.

Following this gift, Bianco directly holds 2,173,307 shares of TuHURA Biosciences common stock. Because this was a gift with no sale proceeds, it reflects a personal transfer of ownership rather than a market transaction in the company’s stock.

Insider Trade Summary

150,000 shares gifted

Mixed 1 txn

Insider Bianco James A.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	150,000	$0.00	--

Holdings After Transaction: Common Stock — 2,173,307 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares gifted: 150,000 shares Price per share for gift: $0.0000 per share Shares owned after transaction: 2,173,307 shares +2 more

5 metrics

Shares gifted 150,000 shares Bona fide gift of common stock on May 28, 2026

Price per share for gift $0.0000 per share Reported transaction price for gifted shares

Shares owned after transaction 2,173,307 shares Direct holdings of James A. Bianco following the gift

Transaction code G (bona fide gift) Indicates non-market gift disposition on Form 4

Gift transactions count 1 transaction Single reported gift in transaction summary

Key Terms

Bona fide gift, Common Stock, Form 4, transaction code G

4 terms

Bona fide gift financial

"The transaction code description is listed as "Bona fide gift" for this transfer."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Common Stock financial

"The security title for the transaction is reported as "Common Stock"."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): { "issuerName": "TuHURA Biosciences, Inc./NV""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code G regulatory

"The filing uses transaction code "G", which denotes a bona fide gift."

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 04:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bianco James A.

(Last)

(First)

(Middle)

10500 UNIVERSITY CENTER DRIVE

SUITE 110

(Street)

TAMPA

FLORIDA

33612

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/28/2026		G⁽¹⁾		150,000	D	$0	2,173,307	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents gifts to adult sons who do not share same household with reporting person.

	/s/ Dan Dearborn as Power of Attorney for James Bianco	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TuHURA Biosciences (HURA) disclose on this Form 4?

TuHURA Biosciences disclosed that CEO James A. Bianco made a bona fide gift of 150,000 shares of the company’s common stock. The transaction was reported as a non-market gift transfer, not a purchase or sale for cash consideration.

How many TuHURA Biosciences (HURA) shares did the CEO gift and to whom?

James A. Bianco gifted 150,000 shares of TuHURA Biosciences common stock. A footnote explains these shares were gifted to his adult sons, who do not share the same household, indicating this was a personal, family-related transfer of ownership.

What are James A. Bianco’s TuHURA Biosciences (HURA) holdings after the reported gift?

After the reported gift transaction, James A. Bianco directly holds 2,173,307 shares of TuHURA Biosciences common stock. This figure reflects his remaining direct ownership position following the transfer of 150,000 shares as a bona fide gift.

Was the TuHURA Biosciences (HURA) CEO’s Form 4 transaction a stock sale?

The Form 4 transaction was not a sale. It is coded as a bona fide gift, meaning 150,000 shares of TuHURA Biosciences common stock were transferred without payment, reflecting a personal transfer rather than an open-market or private sale.

What transaction code is used for the TuHURA Biosciences (HURA) CEO’s Form 4 gift?

The transaction uses code “G,” indicating a bona fide gift of securities. This code clarifies that 150,000 shares of TuHURA Biosciences common stock were disposed of through gifting, distinguishing it from purchases, sales, option exercises, or tax-withholding events.